

RECOMMENDATIONS

1. Studies on chronic kidney disease (CKD) in children should be carried out periodically in the future to help planning for early detection and better management.
2. Future studies should include CKD stage I.
3. More effort should be exerted to comply with the K/DOQI guidelines for initial and periodic investigations and treatment of childhood CKD.
4. More attention should be paid to completion of the medical records of the patients.
5. To plan for increasing the awareness of pediatricians and general practitioners about the early manifestations of CKD.
6. To convince the parents of the importance of regular follow-up for retarding the progression of CKD.
7. Screening for congenital anomalies of the kidney and urinary tract should be considered in the future.

SUMMARY

The term chronic kidney disease (CKD) refers to a condition of irreversible kidney damage that usually progresses to end-stage renal disease, a life-threatening condition without proper renal replacement therapy.

The aim of this work was to analyze the demographic, clinical, and laboratory data of children with CKD stages II-IV admitted to the Alexandria University Children's Hospital during ten years (2002-2011).

The data were collected from the files of 65 patients, tabulated and statistically analyzed. Stages of CKD were defined according to the K/DOQI guidelines and based on the estimated glomerular filtration rate using Schwartz formula. To our knowledge, this study is the first of its kind in Egypt.

The following results were obtained:

1. The age of the children ranged between 3 months and 14 years, with a mean of 5.7 ± 3.9 years.
2. The male: female ratio was 2.25:1.
3. The majority of the cases were from Beheira and Alexandria governorates (50.7% and 46.2% respectively).
4. At presentation, 12.3% of the patients were in stage II, 46.2% in stage III and 41.5% in stage IV CKD.
5. The number of the patients in the second 5 years of the study (2007-2011) was more than double that in the first 5 years (2002-2006).
6. The causes of CKD were: congenital anomalies of the kidney and urinary tract (47.7%), glomerulopathies (13.8%), hereditary nephropathies (12.3%), other renal/urologic diseases (12.3%), multisystemic diseases (7.7%) and unknown (6.2%).
7. Short stature and underweight were found in 36.9% and 18.5% of the patients, respectively.
8. Pallor (67.7%), fever (33.8%), edema (27.7%) and hypertension (21.5%) were the most frequent clinical manifestations at presentation.
9. Proteinuria (40%), pyuria (26.2%) and hematuria (15.4%) were the most frequent urine findings.
10. Anemia was found in 70.8% of the patients, metabolic acidosis in 33.8%, hypocalcemia in 33.8%, hyperphosphatemia in 18.5%, elevated serum alkaline phosphatase in 18.5%, hyperkalemia in 10.8% and hypercholesterolemia and

hypertriglyceridemia in 12.3% of the patients. Hypokalemia was found in one case, and none of the cases had hyponatremia or hypernatremia.

11. Renal biopsy was done in 23% of the patients, 60% of these had idiopathic glomerular diseases.
12. Ultrasonography for the urinary tract was done in all the cases, voiding cystourethrogram was done in 61.5%, renal scintigraphy in 21.5%, and CT scan of the abdomen and pelvis in 6% of the cases.
13. Acute peritoneal dialysis was done to 36.9% of the cases on presentation.
14. Alfacalcidol and calcium carbonate were given to about 2/3 of the patients, sodium bicarbonate to 1/3, other vitamins and iron to less than half, erythropoietin to less than 1/3 (31%) of the cases, antihypertensive drugs to 1/5 of the cases, antibiotics to 1/3, steroids and cyclophosphamide to a minority of the cases, and surgery was done to about 1/5 (21.5%) of the cases. None of the cases received growth hormone.
15. Among stage IV patients, 18.5% did not receive calcium carbonate, 22.2% did not receive alfacalcidol, and 48.1% did not receive sodium bicarbonate and 63% did not receive erythropoietin.
16. The duration of follow-up ranged between 4 months and 10 years with a mean of 3.2 ± 2.5 years.
17. Follow-up was irregular in 47.7% of the cases.
18. More than half (55.4%) of the patients showed deterioration of kidney function during follow-up.

From the aforementioned results, it was concluded that:

1. There are deficiencies in the clinical and work-up data in some of the files.
2. Some important investigations were not done e.g., urine culture and colony count (in some of the patients), echocardiography (in most of the patients) and skeletal X-rays (in all of the patients).
3. The onset of CKD was in the first 5 years of life in the majority of the cases.
4. Congenital anomalies of the kidney and urinary tract were the commonest cause of CKD.
5. There was delay in the diagnosis of CKD.
6. Anemia, proteinuria, growth retardation, metabolic acidosis and hypocalcemia were the most common findings at presentation.

7. Treatment given to the patients was frequently incomplete, compared to the international (K/DOQI) guidelines.
8. Follow-up was irregular in nearly half of the patients.
9. CKD progressed in the majority of the patients followed-up.

Consequently, it was recommended that:

1. Studies on chronic kidney disease (CKD) in children should be carried out periodically in the future to help planning for early detection and better management.
2. Future studies should include CKD stage I.
3. More effort should be exerted to comply with the K/DOQI guidelines for initial and periodic investigations and treatment of childhood CKD.
4. More attention should be paid to completion of the medical records of the patients.
5. To plan for increasing the awareness of pediatricians and general practitioners about the early manifestations of CKD.
6. To convince the parents of the importance of regular follow-up for retarding the progression of CKD.
7. Screening for congenital anomalies of the kidney and urinary tract should be considered in the future.

REFERENCES

1. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int* 2005; 67:2089-100.
2. Mahdavi-Mazdeh M. Why do we need chronic kidney disease screening and which way to go? *Iran J Kidney Dis* 2010; 4:275–81.
3. Barsoum RS. Chronic kidney disease in the developing world. *N Engl J Med* 2006; 354:997–9.
4. VanDeVoorde RG, Warady BA. Management of chronic kidney disease. In: Avner ED, Harmon WE, Niaudet P, Yoshikawa N (eds). *Pediatric Nephrology*. 6thed. Berlin Heidelberg: Springer-Verlag, 2009;1661-92.
5. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. *Am J Kidney Dis* 2002; 39 (Suppl 1): S1-266.
6. Hogg RJ, Furth S, Lemley KV, Portman R, Schwartz GJ, Coresh J, et al. National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. *Pediatrics* 2003; 111:1416-21.
7. Ardissino G, Daccò V, Testa S, Bonaudo R, Claris-Appiani A, Taioli E, et al. Epidemiology of chronic renal failure in children: data from the ItalKid Project. *Pediatrics* 2003; 111: 382–7.
8. Fivush BA, Jabs K, Neu AM, Sullivan EK, Feld L, Kohaut E, et al. Chronic renal insufficiency in children and adolescents: the 1996 annual report of NAPRTCS: North American Pediatric Renal Transplant Cooperative Study. *Pediatr Nephrol* 1998; 12:328-37.
9. Harambat J, van Stralen KJ, Kim JJ, Tizard EJ. Epidemiology of chronic kidney disease in children. *Pediatr Nephrol* 2012; 27:363-73.
10. Schwartz GJ, Hanycock GB, Edelmann CMJr, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. *Pediatrics* 1976; 58: 259-63.
11. Counahan R, Chantler C, Ghazali S, Kirkwood B, Rose F, Barratt TM. Estimation of glomerular filtration rate from plasma creatinine concentration in children. *Arch Dis Child* 1976; 51: 875-8.

12. Eckardt KU, Berns JS, Rocco MV, Kasiske BL. Definition and classification of CKD: the debate should be about patient prognosis--a position statement from KDOQI and KDIGO. *Am J Kidney Dis* 2009; 53: 915-20.
13. Warady BA, Chadha V. Chronic kidney disease in children: the global perspective. *Pediatr Nephrol* 2007; 22:1999-2009.
14. Orta-Sibu N, Exeni RA, Garcia C. Latin America. In: Avner ED, Harmon WE, Niaudet P, Yoshikawa N (eds). *Pediatric Nephrology*. 6thed. Berlin Heidelberg: Springer-Verlag, 2009; 1969–74.
15. Al-Eisa A, Naseef M, Al-Hamad N, Pinto R, Al-Shimeri N, Tahmaz M. Chronic renal failure in Kuwaiti children: an eight-year experience. *Pediatr Nephrol* 2005; 20:1781-5.
16. Hamed RM. The spectrum of chronic renal failure among Jordanian children. *J Nephrol* 2002; 15:130-5.
17. Mong Hiep TT, Janssen F, Ismaili K, Khai Minh D, Vuong Kiet D, Robert A. Etiology and outcome of chronic renal failure in hospitalized children in Ho Chi Minh City, Vietnam. *Pediatr Nephrol* 2008; 23:965–70.
18. Huong NT, Long TD, Bouissou F, Liem NT, Truong DM, Nga do K, et al. Chronic kidney disease in children: the National Paediatric Hospital experience in Hanoi, Vietnam. *Nephrology (Carlton)* 2009; 14:722–7.
19. Olowu WA, Adefehinti O, Aladekomo TA. Epidemiology and clinicopathologic outcome of pediatric chronic kidney disease in Nigeria, a single cenetr study. *Arab J Nephrol Transplant* 2013; 6:105-13.
20. Soylemezoglu O, Duzova A, Yalçinkaya F, Arinsoy T, Süleymanlar G. Chronic renal disease in children aged 5–18 years: a population-based survey in Turkey, the CREDIT-C study. *Nephrol Dial Transplant* 2012; 27 (Suppl 3): iii 146-51.
21. Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Ishani A, et al. US renal data system 2010 Annual Data Report. *Am J Kidney Dis* 2011; 57 (Suppl 1):A8, e1-526.
22. Sreedharan R, Avner ED. Chronic kidney disease. In: Kliegman RM, Stanton BF, Geme JW, Schor NF, Behrman RE (eds). *Nelson Textbook of Pediatrics*. 19thed. Philadelphia: Elsevier, 2011; 1822-5.
23. Kaplan BS, Meyers KEC. Chronic renal failure. In: *Kaplan BS, Meyers KEC (eds). Pediatric Nephrology and Urology*. Philadelphia: Elsevier Mosby, 2004; 250-6.

24. Wühl E, Schaefer F. Therapeutic strategies to slow chronic kidney disease progression. *Pediatr Nephrol* 2008; 23: 705–16.
25. Staples AO, Greenbaum LA, Smith JM, Gipson DS, Filler G, Warady BA, et al. Association between clinical risk factors and progression of chronic kidney disease in children. *Clin J Am Soc Nephrol* 2010; 5: 2172-9.
26. Hughson MD, Douglas-Denton R, Bertram JF, Hoy WE. Hypertension, glomerular number, and birth weight in African Americans and white subjects in the southeastern United States. *Kidney Int* 2006; 69:671–8.
27. McClellan W, Warnock DG, McClure L, Campbell RC, Newsome BB, Howard V, et al. Racial differences in the prevalence of chronic kidney disease among participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort Study. *J Am Soc Nephrol* 2006; 17:1710-5.
28. Contreras G, Lenz O, Pardo V, Borja E, Cely C, Iqbal K, et al. Outcomes in African Americans and Hispanics with lupus nephritis. *Kidney Int* 2006; 69:1846-51.
29. Gonzalez Celedon C, Bitsori M, Tullus K. Progression of chronic renal failure in children with dysplastic kidneys. *Pediatr Nephrol* 2007; 22:1014-20.
30. Wühl E, Schaefer F. Progression of kidney disease and renoprotective therapy in children. In: Geary DF, Schaefer F (eds). *Comprehensive Pediatric Nephrology*. 1sted. Philadelphia: Mosby Elsevier, 2008; 695-708.
31. Eddy A. Pathophysiology of progressive renal disease. In: Avner ED, Harmon WE, Niaudet P, Yoshikawa N (eds). *Pediatric nephrology*. 6thed. Berlin Heidelberg: Springer-Verlag, 2009; 1631-60.
32. VanDeVoorde RG, Mitsnefes MM. Chronic kidney disease in childhood and adolescence. *Adv Chronic Kidney Dis* 2011; 18: 355-61.
33. Ardissino G, Avolio L, Dacco V, Testa S, Marra G, Viganò S, et al. Long-term outcome of vesicoureteral reflux-associated chronic renal failure in children. Data from the ItalKid Project. *J Urol* 2004; 172:305-10.
34. Zandi-Nejad K, Eddy AA, Glassock RJ, Brenner BM. Why is proteinuria an ominous biomarker of progressive kidney disease? *Kidney Int* 2004; 66 (Suppl): S76-89.
35. Ritz E, Gross ML, Dikow R. Role of calcium-phosphorous disorders in the progression of renal failure. *Kidney Int*. 2005; 68 (Suppl 99):S66-70.

36. Saland MJ, Ginsberg H, Fisher EA. Dyslipidemia in pediatric renal disease: epidemiology, pathophysiology, and management. *Curr Opin Pediatr* 2002; 14:197-204.
37. Iyengar AA, Foster BJ. Chronic kidney disease. In: Phade KD, Goodyer P, Bitzan M (eds). *Manual of Pediatric Nephrology*. Berlin Heidelberg: Springer-Verlag, 2014; 373-400.
38. Ortega LM, Arora S. Metabolic acidosis and progression of chronic kidney disease: incidence, pathogenesis, and therapeutic options. *Nefrologia* 2012; 32: 724-30.
39. Kalra OP, Aggarwal A. Rational use of diuretics and pathophysiology of oedema. *Delhi Medicine Update* 2012; 22: 601-10.
40. Rodriguez-Soriano J, Arant BS. Fluid and electrolyte imbalances in children with chronic renal failure. *Am J Kidney Dis* 1986; 7: 268-74.
41. Davidovich E, Davidovits M, Peretz B, Shapira J, Aframian DJ. Elevated salivary potassium in pediatric CKD patients: a novel excretion pathway. *Nephrol Dial Transplant* 2011; 26: 1541-6.
42. Wesseling K, Bakkaloglu S, Salusky I. Chronic kidney disease mineral and bone disorder in children. *Pediatr Nephrol* 2008; 23: 195–207.
43. Mahan JD, Warady BA. Assessment and treatment of short stature in pediatric patients with chronic kidney disease: a consensus statement. *Pediatr Nephrol* 2006; 21: 917-30.
44. Babitt JL, Lin HY. Mechanisms of Anemia in CKD. *J Am Soc Nephrol* 2012; 23: 1631-4.
45. Chan JCM, Williams DM, Roth KS. Kidney failure in infants and children. *Pediatr in Rev* 2002; 23: 47-60.
46. Kogon AJ, Stoep AV, Weiss NS, Smith J, Flynn JT, McCauley E. Depression and its associated factors in pediatric chronic kidney disease. *Pediatr Nephrol* 2013; 28:1855-61.
47. Gerson AC, Wentz A, Abraham AG, Mendley SR, Hooper SR, Butler RW, et al. Health-related quality of life of children with mild to moderate chronic kidney disease. *Pediatrics* 2010; 125: e349-57.
48. Hooper SR, Gerson AC, Butler RW, Gipson DS, Mendley SR. Neurocognitive functioning of children and adolescents with mild-to-moderate chronic kidney disease. *Clin J Am Soc Nephrol* 2011; 6:1824-30.

49. Gulati S, Finberg L, Windle ML, Kaskel FJ, Langman CB. Chronic kidney disease in children. Medscape: Drug & Diseases [Last Updated On: 28 Sep, 2012]. Available from:

<http://emedicine.medscape.com/article/984358-overview>. [Accessed on: 2 Aug, 2014].
50. KDOQI Work Group. KDOQI clinical practice guidelines for nutrition in children with CKD: 2008 update: executive summary. *Am J Kid Dis* 2009, 53 (3 Suppl 2): S11-104.
51. Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children and adolescents. *Pediatr Clin North Am* 1987; 34: 571-9.
52. Bacchetta J, Harambat J, Cochat P, Salusky IB, Wesseling-Perry K. The consequences of chronic kidney disease on bone metabolism and growth in children. *Nephrol Dial Transplant* 2012; 27: 3063–71.
53. KDOQI Work Group. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. *Am J Kidney Dis* 2007; 50:471–530.
54. Neu AM. Immunizations in children with chronic kidney disease. *Pediatr Nephrol* 2012; 27: 1257-63.
55. Daschner M. Drug dosage in children with reduced renal function *Pediatr Nephrol* 2005; 20: 1675-86.
56. Wahba IM, Olyaei AJ, Rozansky D, Bennett WM. Handling of drugs in children with abnormal renal function. In: Avner ED, Harmon WE, Niaudet P, Yoshikawa N (eds). *Pediatric Nephrology*. 6thed. Berlin Heidelberg: Springer-Verlag, 2009. 1693-711.
57. Gipson DS, Hooper S. Neurodevelopmental issues in chronic renal disease. In: Geary DF, Schaefer F (eds). *Comprehensive Pediatric Nephrology*. 1sted. Philadelphia: Mosby Elsevier, 2008; 733-40.
58. Phadle K, Bitzan M, Shetty S. Chronic dialysis. In: Phade KD, Goodyer P, Bitzan M (eds). *Manual of Pediatric Nephrology*. Heidelberg: Springer-Verlag, 2014; 401-28.
59. Marks SD. How have the past 5 years of research changed clinical practice in pediatric nephrology. *Arch Dis Child* 2007; 92: 357-61

60. Phadle K, Goodyer P, Iyengar AA. Renal transplantation. In: Phadle K, Goodyer P, Bitzan M (eds). *Manual of Pediatric Nephrology*. Heidelberg: Springer-Verlag, 2014; 429-44.
61. Harmon WE. Pediatric kidney transplantation. In: Avner ED, Harmon WE, Niaudet P, Yoshikawa N (eds). *Pediatric Nephrology*. 6thed. Berlin, Germany: Springer Verlag Berlin Heidelberg, 2009; 1867-902.
62. Task force on blood pressure control in children. Report of the Second Task Force on blood pressure control in children. *Pediatrics* 1987; 79:1-25.
63. Brugnara C, Oski FJ. Normal mean and lower limits of normal for hemoglobin. In: Brugnara C, Oski FJ, Nathan DG (eds). *Nathan and Oski's Hematology of Infancy and Childhood*. 7thed. Philadelphia: WB Saunders, 2009; 455-66.
64. Aune GJ. Fluids and electrolytes. In: Custer JW, Rau RE (eds). *The Harriet Lane Handbook*. 18thed. Philadelphia: Mosby, 2009; 301-326.
65. Custer JW. Blood chemistries and body fluids. In: Custer JW, Rau RE (eds). *The Harriet Lane Handbook*. 18thed. Philadelphia: Mosby, 2009; 677-88.
66. Centers for Disease Control and Prevention (CDC). Growth charts. CDC 2000. Available from: http://www.cdc.gov/growthcharts/cdc_charts.htm. [Accessed On: 11 Jan, 2012].
67. Kotz S, Balakrishnan N, Read CB, Vidakovic B. *Encyclopedia of Statistical Sciences*. 2nded. Hoboken, New Jersey: Wiley-Interscience; 2006.
68. Kirkpatrick LA, Feeney BC. *A simple guide to IBM SPSS statistics for version 20.0*. Student ed. Belmont, Calif.: Wadsworth, Cengage Learning; 2013.
69. Wong CJ, Moxey-Mims M, Jerry-Fluker J, Warady BA, Furth SL. CKiD (CKD in children) prospective cohort study: a review of current findings. *Am J Kidney Dis* 2012; 60:1002-11.
70. Alebiosu CO, Ayodele OE. The global burden of chronic kidney disease and the way forward. *Ethn Dis* 2005; 15: 418-23.
71. Landau D, Schreiber R, Kleinman A, Vodonos A, Shalev H. Pediatric chronic kidney disease rates in Southern Israel are higher than reported. *F1000 Res* 2013; 2: 186.
72. Mong Hiep TT, Ismaili K, Collart F, van Damme-Lombaerts R, Godefroid N, Ghuysen MS, et al. Clinical characteristics and outcomes of children with stage 3-5 chronic kidney disease. *Pediatr Nephrol* 2010; 25: 935-40.

73. Areses Trapote R, Sanahuja Ibáñez MJ, Navarro M. Epidemiology of chronic kidney disease in Spanish pediatric population: REPIR II Project. *Nefrologia* 2010; 30: 508-17.
74. Esbjörner E, Berg U, Hansson S. Epidemiology of chronic renal failure in children: a report from Sweden 1986-1994, Swedish Pediatric Nephrology Association. *Pediatr Nephrol* 1997; 11: 438-42.
75. Deleau J, Andre JL, Briancon S, Musse JP. Chronic renal failure in children: an epidemiological survey in Lorraine (France) 1975-1990. *Pediatr Nephrol* 1994; 8: 472-6.
76. Bek K, Akman S, Bilge I, Topaloğlu R, Calışkan S, Peru H, et al. Chronic kidney disease in children in Turkey. *Pediatr Nephrol* 2009; 24: 97–806.
77. North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). 2008 annual report. Rockville: EMMES; 2008.
78. Fivush BA, Jabs K, Neu AM, Sullivan EK, Feld L, Kohaut E, et al. Chronic renal insufficiency in children and adolescents: the 1996 annual report of NAPRTCS, North American Pediatric Renal Transplant Cooperative Study. *Pediatr Nephrol* 1998; 12: 328-37.
79. Michael IO, Gabreil OE. Chronic renal failure in children of Benin, Nigeria. *Saudi J Kidney Dis Transpl* 2004; 15: 79-83.
80. Bhimma R, Adhikari M, Asharam K, Connolly C. The spectrum of chronic kidney disease (stages 2-5) in KwaZulu-Natal, South Africa. *Pediatr Nephrol* 2008; 23: 1841-6.
81. Ali El-TM, Abdelraheem MB, Mohamed RM, Hassan EG, Watson AR. Chronic renal failure in Sudanese children: aetiology and outcomes. *Pediatr Nephrol* 2009; 24: 349-53.
82. Vachvanichsanong P, Dissaneewate P, McNeil E. Childhood chronic kidney disease in a developing country. *Pediatr Nephrol* 2008; 23: 1143–7.
83. Odetunde OI, Okafor HU, Uwaezuoke SN, Ezeonwu BU, Adiele KD, Ukoha OM. Chronic kidney disease in children as seen in a tertiary hospital in Enugu, South-East, Nigeria. *Niger J Clin Pract* 2014; 17: 196-200.
84. Kanitkar CM. Chronic kidney disease in children: an Indian perspective. *Med J Arm Forc India (MJAFI)* 2009; 65 : 45-9.

85. Ahmed NF, Hussain HH. Chronic renal failure in children admitted to children Welfare Teaching Hospital. *Iraqi Postgrad Med J* 2008;7: 12-17.
86. Wong H, Mylrea K, Feber J, Drukker A, Filler G. Prevalence of complications in children with chronic kidney disease according to KDOQI. *Kidney Int* 2006; 70: 585-90.
87. Gulati S, Mittal S, Sharma RK, Gupta A. Etiology and outcome of chronic renal failure in Indian children. *Pediatr Nephrol* 1999; 13: 594-6.
88. Orta-Sibu N, Lopez M, Moriyon JC, Chavez JB. Renal diseases in children in Venezuela, South America. *Pediatr Nephrol* 2002;17: 566-9.
89. Miller ME, Williams JA. Chronic renal failure in Jamaican children-an update (2001-2006). *West Indian Med J* 2009; 58: 231-4.
90. Anochie I, Eke F. Chronic renal failure in children: a report from Port Harcourt, Nigeria (1985-2000). *Pediatr Nephrol* 2003; 18: 692-5.
91. Kari JA. Chronic renal failure in children in the Western area of Saudi Arabia. *Saudi J Kidney Dis Transpl* 2006; 17: 19-24.
92. Ahmadzadeh A, Valavi E, Zangeneh Kamali M, Ahmadzadeh A. Chronic kidney disease in Southwestern Iranian children. *Iran J Pediatr* 2009; 19: 147-53.
93. Dodson JL, Jerry-Fluker JV, Ng DK, Moxey-Mims M, Schwartz GJ, Dharnidharka VR, et al. Urological disorders in chronic kidney disease in children cohort: clinical characteristics and estimation of glomerular filtration rate. *J Urol* 2011; 186: 1460-6.
94. Sylvestre LC, Fonseca KP, Stingham AE, Pereira AM, Meneses RP, Pecoits-Filho R. The malnutrition and inflammation axis in pediatric patients with chronic kidney disease. *Pediatr Nephrol* 2007; 22: 864-73.
95. Levin A. The advantage of a uniform terminology and staging system for chronic kidney disease. *Nephrol Dial Transplant* 2003; 18: 1446-51.
96. Fadrowski JJ, Pierce CB, Cole SR, Moxey-Mims M, Warady BA, Furth SL. Hemoglobin decline in children with chronic kidney disease: baseline results from the chronic kidney disease in children prospective cohort study. *Clin J Am Soc Nephrol* 2008; 3:457-62.
97. Saland JM, Pierce CB, Mitsnefes MM, Flynn JT, Goebel J, Kupferman JC, et al. Dyslipidemia in children with chronic kidney disease: a report of the Chronic Kidney Disease in Children (CKiD) study. *Kidney Int* 2010; 78:1154-63.

98. Mitsnefes M, Flynn J, Cohn S, Samuels J, Blydt-Hansen T, Saland J. Masked hypertension associated with left ventricular hypertrophy in children with CKD. *J Am Soc Nephrol* 2010; 21: 137-144.
99. Ishikura K, Uemura O, Hamasaki Y, Ito S, Wada N, Hattori M, et al. Progression to end-stage kidney disease in Japanese children with chronic kidney disease: results of a nationwide prospective cohort study. *Nephrol Dial Transplant* 2014; 29: 878-84.

الملخص العربي

يشير مصطلح "مرض الكلى المزمن" إلى حالة تلف دائم بالكلية تتقدم عادة إلى المرحلة النهائية لمرض الكلى وهي مرحلة تهدد الحياة وتتطلب علاجاً تعويضياً للكلية.

وقد كان الهدف من هذه الرسالة هو تحليل البيانات الديموجرافية والسريرية والمختبرية للأطفال المصابين بمرض الكلى المزمن (المراحل ٢-٤) الذين ادخلوا مستشفى الأطفال الجامعي بالاسكندرية خلال عشرة سنوات (٢٠٠٢-٢٠١١). وقد تم جمع البيانات من ملفات ٦٥ مريضاً وتم جدولتها وتحليلها احصائياً . وتم تحديد مراحل مرض الكلى المزمن تبعاً للدلة الإرشادية لمبادرة جودة نتائج مرض الكلى (K/DOQI) ، وبناء على تقدير معدل الترشيح الكبيبي باستخدام معادلة شوارتز . وتعد هذه الدراسة الأولى من نوعها في مصر.

وقد أمكن الحصول على النتائج التالية :

١. تراوح عمر الأطفال المرضى بين ٤ شهور ، ١٤ سنة ، بمتوسط قدره $٣,٩ \pm ٥,٧$ سنة.
٢. كانت نسبة الذكور إلى الاناث = ٢,٢٥ : ١ .
٣. كان أغلب المرضى من محافظات البحيرة والاسكندرية (٥٠,٧% ، ٤٦,٢% على التوالي).
٤. عند تشخيص المرض كان ١٢,٣% من المرضى في المرحلة (٢) و ٤٦,٢% في المرحلة (٣) و ٤١,٥% في المرحلة (٤) .
٥. كان عدد المرضى في السنوات الخمس الثانية من الدراسة (٢٠٠٧-٢٠١١) أكثر من ضعف عددهم في السنوات الخمس الأولى منها (٢٠٠٢-٢٠٠٦).
٦. كانت أسباب مرض الكلى المزمن كالتالي : الشذوذات الولادية للكلية والمسالك البولية (٤٧,٧%) و أمراض الكبيبات (١٣,٨%) و أمراض الكلى الوراثية (١٢,٣%) و أمراض الكلى والمسالك البولية الأخرى (١٢,٣%) و الأمراض متعددة الأجهزة (٧,٧%) و أسباب غير معلومة (٦,٢%) .
٧. وجد أن ٣٦,٩% من المرضى قصار القامة و ١٨,٥% منهم ناقصى الوزن.
٨. كانت اكثر المظاهر السريرية شيوعاً عند التشخيص هي : الشحوب (٦٧,٧%) و الحمى (٣٣,٨%) و الوزن (الايديما) (٢٧,٧%) و ارتفاع ضغط الدم (٢١,٥%) .
٩. كانت أكثر النتائج البولية شيوعاً هي البيلة البروتينية (٤٠%) و البيلة القحجية (٢٦,٢%) و البيلة الدموية (١٥,٤%) .
١٠. كانت نسبة فقر الدم بين الأطفال المرضى ٧٠,٨% و الحماض الأيضى ٣٣,٨% و نقص الكلسمية ٣٣,٨% و فرط الفوسفاتمية ١٨,٥% و ارتفاع الفوسفاتاز القلوى في المصل ١٨,٥% و فرط اليوتاسمية ١٠,٨% و فرط الكولسترولمية ١٢,٣% و فرط ثلاثى الجلسريدمية ١٢,٣% . و لوحظ نقص اليوتاسمية في حالة واحدة ، ولم يلاحظ نقص أو فرط الصوديومية في أى من الحالات.
١١. أجريت خزعة كلوية في ٢٣% من المرضى ووجد في ٦٠% منها أمراض كيبية غامضة (أولية) .
١٢. أجرى فحص للكلية والمسالك البولية بالموجات فوق الصوتية لجميع الحالات، وفحص شعاعى افرغى للمثانة والاحليل في ٦١,٥% من الحالات و مسح ذرى للكلية في ٢١,٥% من الحالات وفحص بالأشعة المقطعية للبطن والحوض في ٦% من الحالات.
١٣. أجرى ديال صفاقى (بريتونى) حاد فور التشخيص في ٣٦,٩% من الحالات.
١٤. أعطى الألفاكالسيدول و كربونات الكلسيوم لثانى المرضى وبيكربونات الصوديوم لثالث المرضى والفيتامينات الأخرى والحديد لأقل من نصف المرض والارثيروبيتين لأقل من ثلث المرض (٣١%) والعقاقير المخفضة

لضغط الدم لخمس المرضى والمضادات الحيوية لثالث المرضى والستيرويدات والسيكلوفوسفاميد لقلّة من المرضى ، وأجريت جراحات لخمس المرضى تقريباً (٢١,٥%) ولم يعطى هرمون النمو لأى من المرضى.

١٥. بين مرضى المرحلة (٤) لم يعطى كربونات الكالسيوم في ١٨,٥% من الحالات ولم يعطى الألفالكالسيدول في ٢٢,٢% من الحالات ولم يعطى بيكربونات الصوديوم في ٤٨,١% من الحالات ولم يعطى الأريثروبويتين في ٦٣% من الحالات.

١٦. تراوحت مدة المتابعة بين ٤ شهور و ١٠ سنوات بمتوسط $٣,٢ \pm ٢,٥$ سنة .

١٧. كانت متابعة المرضى غير منتظمة في ٤٧,٧% من الحالات .

١٨. حدث تدهور في وظيفة الكلى - أثناء المتابعة - في ٥٥,٤% من الحالات.

ومن هذه النتائج أمكن استنتاج ما يلي :

١. وجد نقص في البيانات السريرية وبيانات الاستقصاء (الفحوص) في ملفات بعض المرضى.
٢. لم تجرى بعض الفحوص الهامة في بعض المرضى (مثل مزرعة البول وعد الميكروبات) أو في كل المرضى (مثل اشعة العظام وفحص القلب بالموجات فوق الصوتية) .
٣. بدأ مرض الكلى المزمن في معظم المرضى في الخمس سنوات الأولى من العمر.
٤. كانت الشذوذات الولادية للكلى والمسالك البولية هي أكثر أسباب مرض الكلى المزمن.
٥. كان هناك تأخير في تشخيص مرض الكلى المزمن في الأطفال.
٦. كانت أكثر النتائج شيوعاً بين الأطفال المصابين بمرض الكلى المزمن هي فقر الدم والبيلة البروتينية و قصر القامة والحماض الأيضى ونقص الكالسيوم.
٧. كان العلاج الذى تلقاه المرضى غير كامل في مرات كثيرة وذلك بالمقارنة بالأدلة العلاجية الإرشادية الدولية.
٨. كانت المتابعة غير منتظمة فيما يقرب من نصف المرضى.
٩. إزدادت وظيفة الكلى تدهوراً في غالبية المرضى أثناء المتابعة .

وبالتالى يمكن التوصية بما يلى :-

١. يجب أن تجرى دراسات دورية في المستقبل على الأطفال مرضى الكلى المزمن ، لتساعد في التخطيط من أجل تشخيص مبكر وعلاج أفضل للمرض.
٢. يجب أن تشمل الدراسات المستقبلية المرحلة (١) من مرض الكلى المزمن.
٣. يجب بذل مزيد من الجهد للالتزام بالأدلة الإرشادية الدولية في استقصاء وعلاج مرض الكلى المزمن في الأطفال.
٤. يجب توجيه مزيد من الإهتمام لإستكمال الملفات الطبية للمرضى.
٥. يجب التخطيط لزيادة وعى أطباء الأطفال وأطباء الممارسة العامة بالمظاهر المبكرة لمرض الكلى المزمن.
٦. يجب إقناع آباء الأطفال المرضى بأهمية الإنتظام في المتابعة الدورية أطفالهم للحد من تقدم المرض.
٧. يجب التفكير مستقبلاً في إجراء مسح شامل للشذوذات الولادية للكلى والمسالك البولية.

دراسة الأطفال المصابين بمرض الكلى المزمن (المراحل ٢-٤) الذين أدخلوا مستشفى
الأطفال الجامعي بالإسكندرية خلال عشرة سنوات

رسالة علمية

مقدمة لكلية الطب - جامعة الإسكندرية
إيفاءً جزئياً لشروط للحصول على درجة

الماجستير في طب الأطفال

مقدمة من

نرفين بهنسي علي قرقورة

بكالوريوس الطب والجراحة - الإسكندرية

كلية الطب
جامعة الإسكندرية
٢٠١٥

دراسة الأطفال المصابين بمرض الكلى المزمن (المراحل ٢-٤) الذين أدخلوا مستشفى
الأطفال الجامعي بالإسكندرية خلال عشرة سنوات

مقدمة من

نرفين بهنسي علي قرقورة

بكالوريوس الطب والجراحة- الإسكندرية

للحصول على درجة

الماجستير في طب الأطفال

موافقون

.....

.....

.....

لجنة المناقشة والحكم على الرسالة

أ.د/ محمود عادل عبد المنعم محمود
أستاذ طب الاطفال
كلية الطب
جامعة الإسكندرية

أ.د/ زهيرة متولي جاد إمام
أستاذ الباثيات
المعهد العالي للصحة العامة
جامعة الإسكندرية

أ.د/ محمد علاء الدين حسن ثابت
أستاذ طب الاطفال
كلية الطب
جامعة الإسكندرية

التاريخ:

السادة المشرفون

أ.د/ محمود عادل عبد المنعم محمود

أستاذ طب الأطفال

كلية الطب

جامعة الإسكندرية

.....

أ.د/ محمود محي الدين إبراهيم القرش

أستاذ طب الأطفال

كلية الطب

جامعة الإسكندرية

.....